HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $497, high $798, with mid-point at $647.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$647
Margin of safety
+34.1%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$426.37Price
Low $496.77
Mid $647.26
High $798.49
HCA trades against a final fair-value range of $496.77-$798.49, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Local market density and scale
Local market density and scale advantages driving industry-leading margins.
Demographic tailwinds with an aging
Demographic tailwinds with an aging population ensuring consistent volume.
Bull thesis
Market under-appreciates the durability of HCA's local market density and the resultant ROIC/WACC spread.
Free cash flow for HCA (HCA) is computed as operating cash flow minus capital expenditure. We report both the absolute level and the FCF margin against revenue, with five years of trajectory.
Operating cash flow is the primary signal: when OCF is negative or significantly below net income, the cash-flow subsection flags the divergence and traces the cause to working-capital, deferred-revenue, or earnings-quality effects.
Capital expenditure is reported as a percentage of revenue alongside the absolute number. Heavy investment phases are separated from harvesting phases so reinvestment intent is legible.
The financing activity row tracks dividends paid, share repurchases, and net debt issuance. Together with FCF, it answers whether buybacks and dividends are funded organically or by issuing debt.
FAQ
HCA — frequently asked questions
Based on our latest analysis, HCA looks meaningfully undervalued. The current price is $426 versus a composite fair-value midpoint of $647 (range $497–$798), which implies roughly 51.8% upside to the midpoint.
Our composite fair-value range for HCA is $497–$798, with a midpoint of $647. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for HCA's archetype.
Our current rating for HCA is Strong Buy with a confidence score of 88/100. HCA is rated Strong Buy at $426.37 versus the reconciled fair value midpoint of $647.26, implying +51.81% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for HCA are: Severe Reimbursement Cuts; Structural Labor Shortage; Debt Cost Spiral. The single biggest risk is Severe Reimbursement Cuts: Government payers drastically compress Medicare/Medicaid rates to manage ballooning deficits, crushing margins.
Our current rating for HCA is Strong Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($497–$798) versus the current price of $426.
HCA is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for HCA.